<! –

->

November 2, 2018 – By Catherine Smith

On November, 15. Investors expect MediWound Ltd. (NASDAQ: MDWD) to report its quarterly earnings, Faxor reports. EPS of $ -0.19 is 18.75% down from 2017's $ -0.16 EPS. 26.67% negative EPS growth is what Wall Street predicts after $ -0.15 reported EPS last quarter. $ 5.8 was the last price.Since November 2, 2017 it's 13.04% down thus uptrending. The stock underperformed the S & P500 by 2.58%.

MediWound Ltd. (NASDAQ: MDWD) Ratings Coverage

In total 2 badysts cover Mediwound (NASDAQ: MDWD). "Buy" rating has 2, "Sell" are 0, while 0 are "Hold". 100% are bullish. 3 are the (NASDAQ: MDWD) 's badyst reports since May 10, 2018 according to StockzIntelligence Inc. In Thursday, May 10 report Oppenheimer maintained it with "Buy" rating and $ 1400 target. In Monday, June 11 report Oppenheimer maintained the stock with "Buy" rating.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics in Israel.The company has $ 157.64 million market cap. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns.Last it reported negative earnings. The firm also develops EscharEx, which is in Phase II clinical trials for debridement of chronic and other hard-to-heal wounds.